651 A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors

• Angela Alistar,
• Alain Mita,
• Devalingam Mahalingam,
• Anthony El-Khoueiry,
• Jeongjun Kim,
• Hyunji Ahn,
• Jinho Choi,
• Seung-Hee Ryu,
• Jiye Ahn,
• Bae Jung Choi,
• Hwankyu Kang,
• Yeong-In Yang,
• Seung-Joo Lee,
• Borami Jeon,
• Stefan Proniuk,
• Kiyean Nam

Affiliations

Angela Alistar

2Atlantic Health System, Morristown, NJ, USA

Alain Mita

Cedars-Sinai Medical Center, Los Angeles, California, USA

Devalingam Mahalingam

8Northwestern University, Chicago, IL, USA

Anthony El-Khoueiry

4USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA

Jeongjun Kim

4Qurient Co., Ltd., Seongnam-si, Gyeonggi-do, Republic of Korea

Hyunji Ahn

4Qurient Co., Ltd., Seongnam-si, Gyeonggi-do, Republic of Korea

Jinho Choi

4Qurient Co., Ltd., Seongnam-si, Gyeonggi-do, Republic of Korea

Seung-Hee Ryu

4Qurient Co., Ltd., Seongnam-si, Gyeonggi-do, Republic of Korea

Jiye Ahn

4Qurient Co., Ltd., Seongnam-si, Gyeonggi-do, Republic of Korea

Bae Jung Choi

4Qurient Co., Ltd., Seongnam-si, Gyeonggi-do, Republic of Korea

Hwankyu Kang

4Qurient Co., Ltd., Seongnam-si, Gyeonggi-do, Republic of Korea

Yeong-In Yang

4Qurient Co., Ltd., Seongnam-si, Gyeonggi-do, Republic of Korea

Seung-Joo Lee

4Qurient Co., Ltd., Seongnam-si, Gyeonggi-do, Republic of Korea

Borami Jeon

4Qurient Co., Ltd., Seongnam-si, Gyeonggi-do, Republic of Korea

Stefan Proniuk

4Qurient Co., Ltd., Seongnam-si, Gyeonggi-do, Republic of Korea

Kiyean Nam

4Qurient Co., Ltd., Seongnam-si, Gyeonggi-do, Republic of Korea